# Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer

> **NCT02299141** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 20 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Non-Small Cell Lung Cancer
- Nonsmall Cell Lung Cancer

## Interventions

- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT02299141
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-07
- **Primary completion:** 2020-01-09
- **Final completion:** 2025-04-23
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02299141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02299141, "Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02299141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*